Clinical study of gemcitabine plus cisplatin combined with in the treatment of advanced non-Small cell lung cancer

VernacularTitle:吉西他滨联合顺铂治疗晚期非小细胞肺癌临床观察
Author: Yongling LIU ; Zhongmin WANG ; Keliang LU ; Yong ZHU ; Nansheng YU ; Jiyue WAN
Publication Type:Journal Article
Keywords: Carcinoma non-small-cell lung cancer; Gemcitabine; Cisplatin
From: Chinese Journal of Primary Medicine and Pharmacy 2010;17(4):445-446
CountryChina
Language:Chinese
Abstract: Objective To investigate the efficacy and toxicities of gemcitabine and cisplatin as a chemother-apy regimen for patients with advanced non-small cell lung cancer (NSCLC). Methods Thirty-five patients with NSCLC were enrolled in this study. C, emeitabine was given on day 1 and 8 at a dose of 1000 mg/m~2 and cisplatin at a dose of 25 mg/m~2 on day 1 to 3. The chemotherapy was repeated every 28 days, after 2 cycles for evaluating response. Results Complete response (CR), partial response (PR) ,stable disease (SD) and progressive disease (PD) were observed in 0,14,16 and 5 cases, respectively, with a response rate (RR) of 40. 0%. The RR in initial treatment group was found more than that in the retreatment group (52. 2% vs 16.7% ,P<0. 05).The main toxicities were tol-erable, which included myelosuppression, nausea, vomiting, and liver damage. Conclusion Gemcitabine combined with cisplatin is effective and safe in the treatment of NSCLC, especially in the initial treatment patients.